EPO and glaucoma: In the experimental glaucoma models, treatments with minocycline, X-ray radiation or a modified erythropoietin (EPO) help preserve RGCs and ameliorate the pathological progression at least in part by inhibiting microglia/macrophages activation [32,33,34,35], suggesting microglial activation being a potential target for resisting inflammatory injury and maintaining RGC survival.